Cas no 150412-80-9 (Gal β(1-4)Glc-β-MP)

Gal β(1-4)Glc-β-MP is a glycosyl donor derivative used in synthetic glycosylation reactions, particularly for the formation of β(1-4)-linked disaccharides. Its key advantage lies in the β-mannopyranosyl (β-MP) leaving group, which enhances stereoselectivity and yield in glycosidic bond formation. The compound is valuable for the controlled synthesis of complex oligosaccharides, offering improved reactivity and stability compared to traditional donors. Its application spans glycobiology research, vaccine development, and the production of bioactive glycoconjugates. The product is characterized by high purity and consistency, making it a reliable reagent for demanding synthetic workflows.
Gal β(1-4)Glc-β-MP structure
Gal β(1-4)Glc-β-MP structure
Product Name:Gal β(1-4)Glc-β-MP
CAS No:150412-80-9
MF:C19H28O12
MW:448.418427467346
MDL:MFCD11112178
CID:1003756
PubChem ID:87560706
Update Time:2025-10-31

Gal β(1-4)Glc-β-MP Chemical and Physical Properties

Names and Identifiers

    • 4-Methoxyphenyl 4-O-(beta-D-Galactopyranosyl)-beta-D-glucopyranoside
    • Gal beta(1-4)Glc-beta-MP
    • (2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-(4-methoxyphenoxy)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
    • 4-METHOXYPHENYL 4-O-(B-D-GALACTOPYRANOSYL)-B-D-GLUCOPYRANOSIDE
    • Gal beta(1-4)Glc-beta-MP Galβ(1-4)Glc-β-MP
    • 4-Methoxyphenyl 4-O-(β-D-Galactopyranosyl)-β-D-glucopyranoside
    • Galβ(1-4)Glc-&beta
    • I07-406
    • -MP
    • p-methoxyphenyl lactoside
    • GALΒ(1-4)GLC-Β-MP
    • LacMP
    • Galβ(1-4)Glc-βGalβ(1-4)Glc-β4-Methoxyphenyl 4-O-β-D-Galactopyranosyl-β-D-glucopyranoside
    • 4-Methoxyphenyl 4-O-(beta-D-Galactopyranosyl)-beta-D-glucopyranoside LacMP
    • 4-Methoxyphenyl 4-O-beta-D-galactopyranosyl-beta-D-glucopyranoside
    • beta-D-Glucopyranoside, 4-methoxyphenyl 4-O-beta-D-galactopyranosyl-
    • AS-71350
    • (2S,3R,4S,5R,6R)-2-(((2R,3S,4R,5R,6S)-4,5-Dihydroxy-2-(hydroxymethyl)-6-(4-methoxyphenoxy)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
    • HY-W145558
    • Gal
    • (2S,3R,4S,5R,6R)-2-{[(2R,3S,4R,5R,6S)-4,5-DIHYDROXY-2-(HYDROXYMETHYL)-6-(4-METHOXYPHENOXY)OXAN-3-YL]OXY}-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL
    • PJFQMORRZLJWQE-BAGUKLQFSA-N
    • T71808
    • CS-0214548
    • AKOS030549416
    • DTXSID80466382
    • A-MP
    • A(1-4)Glc-
    • 150412-80-9
    • Gal β(1-4)Glc-β-MP
    • MDL： MFCD11112178
    • Inchi： 1S/C19H28O12/c1-27-8-2-4-9(5-3-8)28-18-16(26)14(24)17(11(7-21)30-18)31-19-15(25)13(23)12(22)10(6-20)29-19/h2-5,10-26H,6-7H2,1H3/t10-,11-,12+,13+,14-,15-,16-,17-,18-,19+/m1/s1
    • InChI Key： PJFQMORRZLJWQE-BAGUKLQFSA-N
    • SMILES： O([C@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)O)[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC1C=CC(=CC=1)OC

Computed Properties

  • Exact Mass: 448.15800
  • Monoisotopic Mass: 448.15807632g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 7
  • Hydrogen Bond Acceptor Count: 12
  • Heavy Atom Count: 31
  • Rotatable Bond Count: 7
  • Complexity: 544
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 10
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -2.9
  • Topological Polar Surface Area: 188

Experimental Properties

  • Density: 1.585
  • Boiling Point: 742.152°C at 760 mmHg
  • Flash Point: 402.639°C
  • Refractive Index: 1.641
  • PSA: 187.76000
  • LogP: -3.30190

Gal β(1-4)Glc-β-MP Security Information

  • Regulatory Condition Code：Class Q (sugars, alkaloids, antibiotics, hormones)
  • Storage Condition：<0°C

Gal β(1-4)Glc-β-MP Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
G596635-25mg
Gal β(1-4)Glc-β-MP
 150412-80-9
25mg
 $ 50.00 2022-06-04
TRC
G596635-50mg
Gal β(1-4)Glc-β-MP
 150412-80-9
50mg
 $ 65.00 2022-06-04
TRC
G596635-200mg
Gal β(1-4)Glc-β-MP
 150412-80-9
200mg
 $ 135.00 2022-06-04
eNovation Chemicals LLC
D768350-1g
-D-Glucopyranoside, 4-methoxyphenyl 4-O-D-galactopyranosyl-
 150412-80-9 96.0%
1g
 $540 2023-05-18
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
M1805-1G
Galβ(1-4)Glc-β-MP
 150412-80-9 >96.0%(HPLC)(qNMR)
1g
 ￥685.00 2024-04-17
Chemenu
CM409991-1g
4-Methoxyphenyl 4-O-(b-D-galactopyranosyl)-b-D-glucopyranoside
 150412-80-9 95%+
1g
 $*** 2023-03-30
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
G863433-250mg
Galβ(1-4)Glc-β-MP
 150412-80-9 ≥96%(HPLC)
250mg
 ￥210.60 2022-01-14
Biosynth
OM08847-100 mg
4-Methoxyphenyl 4-O-(b-D-galactopyranosyl)-b-D-glucopyranoside
 150412-80-9
100MG
 $63.53 2023-01-03
Biosynth
OM08847-250 mg
4-Methoxyphenyl 4-O-(b-D-galactopyranosyl)-b-D-glucopyranoside
 150412-80-9
250MG
 $127.05 2023-01-03
Biosynth
OM08847-500 mg
4-Methoxyphenyl 4-O-(b-D-galactopyranosyl)-b-D-glucopyranoside
 150412-80-9
500MG
 $190.58 2023-01-03

Gal β(1-4)Glc-β-MP Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:150412-80-9)Gal β(1-4)Glc-β-MP
Order Number:A1017634
Stock Status:in Stock
Quantity:1g
Purity:99%
Pricing Information Last Updated:Thursday, 29 August 2024 15:20
Price ($):189.0

Gal β(1-4)Glc-β-MP Related Literature

Related Categories

Additional information on Gal β(1-4)Glc-β-MP

Recent Advances in the Study of Gal β(1-4)Glc-β-MP and Compound 150412-80-9: Implications for Glycobiology and Therapeutic Development

The compound with the CAS number 150412-80-9 and the product Gal β(1-4)Glc-β-MP have recently garnered significant attention in the field of glycobiology and medicinal chemistry. These molecules are pivotal in understanding carbohydrate-protein interactions, which play a crucial role in various biological processes, including cell signaling, immune response, and pathogen recognition. This research briefing aims to synthesize the latest findings related to these compounds, highlighting their structural characteristics, biological activities, and potential therapeutic applications.

Recent studies have elucidated the structural properties of Gal β(1-4)Glc-β-MP, a synthetic disaccharide derivative that mimics natural glycans. This compound has been utilized as a tool to investigate the binding specificities of lectins and other carbohydrate-binding proteins. Advanced NMR and X-ray crystallography techniques have revealed its conformational flexibility and its ability to form stable complexes with target proteins. These insights are instrumental in designing glycomimetics for therapeutic interventions.

Compound 150412-80-9, on the other hand, has been identified as a promising scaffold for drug development due to its unique chemical properties. Recent pharmacological evaluations have demonstrated its potential as an inhibitor of specific glycosidases, enzymes that are often implicated in metabolic disorders and infectious diseases. In vitro and in vivo studies have shown that this compound exhibits high selectivity and low cytotoxicity, making it a viable candidate for further preclinical development.

One of the most groundbreaking findings in this area is the application of Gal β(1-4)Glc-β-MP in cancer research. Researchers have discovered that this compound can modulate the activity of galectins, a family of proteins that are overexpressed in many cancers. By interfering with galectin-mediated signaling pathways, Gal β(1-4)Glc-β-MP has shown potential in reducing tumor growth and metastasis in animal models. These results open new avenues for the development of glycan-based anticancer therapies.

In addition to its therapeutic potential, Gal β(1-4)Glc-β-MP has also been employed in diagnostic applications. Its ability to selectively bind to certain pathogens has been leveraged in the design of biosensors for rapid detection of bacterial and viral infections. This dual functionality—both therapeutic and diagnostic—underscores the versatility of this compound in biomedical research.

The synthesis and optimization of compound 150412-80-9 have also seen significant progress. Recent publications describe novel synthetic routes that improve yield and purity, addressing previous challenges in large-scale production. Computational modeling has further aided in understanding its structure-activity relationship, enabling the design of derivatives with enhanced pharmacological profiles. These advancements are critical for translating this compound from the bench to the clinic.

Despite these promising developments, challenges remain. The pharmacokinetics and biodistribution of both Gal β(1-4)Glc-β-MP and compound 150412-80-9 require further investigation to ensure their efficacy and safety in humans. Additionally, the cost of synthesis and scalability issues must be addressed to facilitate their commercial viability. Collaborative efforts between academia and industry will be essential to overcome these hurdles.

In conclusion, the latest research on Gal β(1-4)Glc-β-MP and compound 150412-80-9 highlights their significant potential in glycobiology and therapeutic development. From elucidating fundamental biological mechanisms to pioneering new treatments, these compounds are at the forefront of innovation. Continued investment in research and development will be crucial to fully realize their benefits and bring novel therapies to patients.

150412-80-9 (Gal β(1-4)Glc-β-MP) Related Products

Recommended suppliers
Amadis Chemical Company Limited
(CAS:150412-80-9)Gal β(1-4)Glc-β-MP
A1017634
Purity:99%
Quantity:1g
Price ($):189.0
Email